Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 1

Status

Completed 5Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Lymphoma 155Leukemia 127Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Non-Hodgkin 81Leukemia, Myeloid, Acute 80Lymphoma, Large B-Cell, Diffuse 75Multiple Myeloma 71Lymphoma, Follicular 64Hodgkin Disease 64Breast Neoplasms 64Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Mantle-Cell 62Burkitt Lymphoma 60Myelodysplastic Syndromes 55Lymphoma, Large-Cell, Immunoblastic 53Sarcoma 41Lymphoma, B-Cell, Marginal Zone 40Neuroblastoma 37Central Nervous System Neoplasms 34Neoplasms, Plasma Cell 32Leukemia, Myeloid, Chronic-Phase 32Ovarian Neoplasms 31Leukemia, Myeloid, Accelerated Phase 30Myeloproliferative Disorders 28Dendritic Cell Sarcoma, Interdigitating 28Recurrence 27Congenital Abnormalities 27Blast Crisis 26Neutropenia 24Anemia, Refractory, with Excess of Blasts 22

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × Filgrastim × Clear all
NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

University of Wisconsin, Madison

Phase 2 Completed
29 enrolled 15 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05520723 2025-12-04

PRIMED

MedSIR

Phase 2 Completed
50 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03036488 2025-10-29

MK-3475-522

Merck Sharp & Dohme LLC

Phase 3 Completed
1,174 enrolled 1 FDA
Breast

Triple Negative Breast Neoplasms

NCT03197935 2023-10-26

IMpassion031

Hoffmann-La Roche

Phase 3 Completed
333 enrolled 18 charts
Breast

Triple Negative Breast Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Hoffmann-La Roche

Phase 1 Completed
83 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡